Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Sheila Lumley(Anna Needs Neuroblastoma Answers), Denise O’Donnell(Anna Needs Neuroblastoma Answers), Nicole Stoesser(Anna Needs Neuroblastoma Answers), Philippa C. Matthews(Anna Needs Neuroblastoma Answers), Alison Howarth(Anna Needs Neuroblastoma Answers), Stephanie B. Hatch(Anna Needs Neuroblastoma Answers), Brian D. Marsden(Anna Needs Neuroblastoma Answers), Stuart Cox(Anna Needs Neuroblastoma Answers), Tim James(Anna Needs Neuroblastoma Answers), Fiona C Warren(Anna Needs Neuroblastoma Answers), Liam J Peck(Anna Needs Neuroblastoma Answers), Thomas Ritter(Anna Needs Neuroblastoma Answers), Zoe de Toledo(Anna Needs Neuroblastoma Answers), Laura Warren(Anna Needs Neuroblastoma Answers), David Axten(Anna Needs Neuroblastoma Answers), Richard J. Cornall(Anna Needs Neuroblastoma Answers), E Yvonne Jones(Anna Needs Neuroblastoma Answers), David I. Stuart(Anna Needs Neuroblastoma Answers), Gavin Screaton(Anna Needs Neuroblastoma Answers), Daniel Ebner(Anna Needs Neuroblastoma Answers), Sarah Hoosdally(Anna Needs Neuroblastoma Answers), Meera Chand(Anna Needs Neuroblastoma Answers), Derrick W. Crook(Anna Needs Neuroblastoma Answers), Anne-Marie O’Donnell(Anna Needs Neuroblastoma Answers), Christopher P. Conlon(Anna Needs Neuroblastoma Answers), Koen B. Pouwels(Anna Needs Neuroblastoma Answers), A. Sarah Walker(Anna Needs Neuroblastoma Answers), Tim Peto(Anna Needs Neuroblastoma Answers), Susan Hopkins(Anna Needs Neuroblastoma Answers), A Sarah Walker(Anna Needs Neuroblastoma Answers), Katie Jeffery(Anna Needs Neuroblastoma Answers), David W. Eyre(Anna Needs Neuroblastoma Answers)
New England Journal of Medicine
December 23, 2020
Cited by 1,026Open Access
Full Text

Abstract

BACKGROUND: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear. METHODS: We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in seropositive and seronegative health care workers attending testing of asymptomatic and symptomatic staff at Oxford University Hospitals in the United Kingdom. Baseline antibody status was determined by anti-spike (primary analysis) and anti-nucleocapsid IgG assays, and staff members were followed for up to 31 weeks. We estimated the relative incidence of PCR-positive test results and new symptomatic infection according to antibody status, adjusting for age, participant-reported gender, and changes in incidence over time. RESULTS: A total of 12,541 health care workers participated and had anti-spike IgG measured; 11,364 were followed up after negative antibody results and 1265 after positive results, including 88 in whom seroconversion occurred during follow-up. A total of 223 anti-spike-seronegative health care workers had a positive PCR test (1.09 per 10,000 days at risk), 100 during screening while they were asymptomatic and 123 while symptomatic, whereas 2 anti-spike-seropositive health care workers had a positive PCR test (0.13 per 10,000 days at risk), and both workers were asymptomatic when tested (adjusted incidence rate ratio, 0.11; 95% confidence interval, 0.03 to 0.44; P = 0.002). There were no symptomatic infections in workers with anti-spike antibodies. Rate ratios were similar when the anti-nucleocapsid IgG assay was used alone or in combination with the anti-spike IgG assay to determine baseline status. CONCLUSIONS: The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months. (Funded by the U.K. Government Department of Health and Social Care and others.).


Related Papers

No related papers found

Powered by citation graph analysis